These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9558174)

  • 1. An open study of pamidronate in the treatment of refractory ankylosing spondylitis.
    Maksymowych WP; Jhangri GS; Leclercq S; Skeith K; Yan A; Russell AS
    J Rheumatol; 1998 Apr; 25(4):714-7. PubMed ID: 9558174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis.
    Maksymowych WP; Jhangri GS; Fitzgerald AA; LeClercq S; Chiu P; Yan A; Skeith KJ; Aaron SL; Homik J; Davis P; Sholter D; Russell AS
    Arthritis Rheum; 2002 Mar; 46(3):766-73. PubMed ID: 11920413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinimetric evaluation of the bath ankylosing spondylitis metrology index in a controlled trial of pamidronate therapy.
    Jauregui E; Conner-Spady B; Russell AS; Maksymowych WP
    J Rheumatol; 2004 Dec; 31(12):2422-8. PubMed ID: 15570645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy.
    Maksymowych WP; Lambert R; Jhangri GS; Leclercq S; Chiu P; Wong B; Aaron S; Russell AS
    J Rheumatol; 2001 Jan; 28(1):144-55. PubMed ID: 11196517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis.
    Toussirot E; Wendling D
    Curr Opin Rheumatol; 2007 Jul; 19(4):340-5. PubMed ID: 17551363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalidomide for severe refractory ankylosing spondylitis: a 6-month open-label trial.
    Wei JC; Chan TW; Lin HS; Huang F; Chou CT
    J Rheumatol; 2003 Dec; 30(12):2627-31. PubMed ID: 14719205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Six months open label trial of leflunomide in active ankylosing spondylitis.
    Haibel H; Rudwaleit M; Braun J; Sieper J
    Ann Rheum Dis; 2005 Jan; 64(1):124-6. PubMed ID: 15608310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of mesalazine (Salofalk) in an open study of 20 patients with ankylosing spondylitis.
    van Denderen JC; van der Horst-Bruinsma I; Bezemer PD; Dijkmans BA
    J Rheumatol; 2003 Jul; 30(7):1558-60. PubMed ID: 12858458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
    Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Grassnickel L; Rudwaleit M; Sieper J; Braun J
    Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.
    Braun J; Brandt J; Listing J; Zink A; Alten R; Burmester G; Golder W; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Reddig J; Sieper J
    Arthritis Rheum; 2003 Aug; 48(8):2224-33. PubMed ID: 12905476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reference centile charts for measures of disease activity, functional impairment, and metrology in ankylosing spondylitis.
    Taylor AL; Balakrishnan C; Calin A
    Arthritis Rheum; 1998 Jun; 41(6):1119-25. PubMed ID: 9627023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany].
    Brandt J; Westhoff G; Rudwaleit M; Listing J; Zink A; Braun J; Sieper J
    Z Rheumatol; 2003 Jun; 62(3):264-73. PubMed ID: 12827403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study.
    Tan AL; Marzo-Ortega H; O'Connor P; Fraser A; Emery P; McGonagle D
    Ann Rheum Dis; 2004 Sep; 63(9):1041-5. PubMed ID: 15066864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement.
    Rejón E; Giménez MD; Mayordomo L; Rodríguez S; González MP; Marenco JL
    Scand J Rheumatol; 2004; 33(5):323-6. PubMed ID: 15513681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.
    Brandt J; Haibel H; Cornely D; Golder W; Gonzalez J; Reddig J; Thriene W; Sieper J; Braun J
    Arthritis Rheum; 2000 Jun; 43(6):1346-52. PubMed ID: 10857793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Swedish version of the Bath ankylosing spondylitis disease activity index. Reliability and validity.
    Waldner A; Cronstedt H; Stenström CH
    Scand J Rheumatol Suppl; 1999; 111():10-6. PubMed ID: 10503554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
    Brandt J; Listing J; Haibel H; Sörensen H; Schwebig A; Rudwaleit M; Sieper J; Braun J
    Rheumatology (Oxford); 2005 Mar; 44(3):342-8. PubMed ID: 15561737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.